Key result
Cardiac allograft vasculopathy remains a major limiting factor in long-term survival after heart transplantation, though advances in imaging, diagnostics, and pharmacology are improving management.
Why the study?
Cardiac allograft vasculopathy remains a major limiting factor in the long-term survival of heart transplant recipients.
Answers are grounded in this paper and cite their sources.
This review highlights the evolving understanding of cardiac allograft vasculopathy pathogenesis, diagnostic modalities, and pharmacological advances in heart transplant recipients.
Cardiac allograft vasculopathy remains a major limiting factor in the long-term survival of the heart transplant recipient. Our understanding of its pathogenesis is continuously evolving as advances in imaging modalities have allowed a direct window into the natural history of the disease. Innovation in diagnostic modalities has spurred the proliferation of prognostic tools and biomarkers. And in parallel, pharmacological advances have emerged that have helped ameliorate the disease's progressive course.
No takes yet. Share an insight, caveat, or question.
Nikolova et al. (2019) conducted a review in Cardiac allograft vasculopathy. Cardiac allograft vasculopathy remains a major limiting factor in long-term survival after heart transplantation, though advances in imaging, diagnostics, and pharmacology are improving management.
Synapse has enriched 10 related papers. Consider them for comparative context: